![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA
9-Tetrahydrocannabinol in C57BL/6 MiceDepartments of Pharmacology and Toxicology (J.P.B., N.E.K) and Pathobiology and Diagnostic Investigation (J.R.H., K.J.W.) and Center for Integrative Toxicology (J.P.B., P.W.F.K., J.R.H, N.E.K.), Michigan State University, East Lansing, Michigan
9-Tetrahydrocannabinol (
9-THC) has been widely established as a modulator of host immune responses. Accordingly, the objective of the present study was to examine the effects of
9-THC on the immune response within the lungs and associated changes in the morphology of the bronchiolar epithelium after one challenge with a nonlethal dose of the influenza virus A/PR/8 (PR8). C57BL/6 mice were treated by oral gavage with
9-THC and/or vehicle (corn oil) for 5 consecutive days. On day 3, mice were instilled intranasally with 50 plaque-forming units of PR8 and/or vehicle (saline) 4 h before
9-THC exposure. Mice were subsequently killed 7 and 10 days postinfection (dpi). Viral hemagglutinin 1 (H1) mRNA levels in the lungs were increased in a dose-dependent manner with
9-THC treatment. Enumeration of inflammatory cell types in bronchoalveolar lavage fluid showed an attenuation of macrophages and CD4+ and CD8+ T cells in
9-THC-treated mice compared with controls. Likewise, the magnitude of inflammation and virus-induced mucous cell metaplasia, as assessed by histopathology, was reduced in
9-THC-treated mice by 10 dpi. Collectively, these results suggest that
9-THC treatment increased viral load, as assessed by H1 mRNA levels, through a decrease in recruitment of macrophages and lymphocytes, particularly CD4+ and CD8+ T cells, to the lung.
Address correspondence to: Dr. Norbert E. Kaminski, 315 National Food Safety and Toxicology Building, Michigan State University, East Lansing, MI 48824-1317. E-mail address: kamins11{at}msu.edu
This article has been cited by other articles:
![]() |
J. A. Voynow and B. K. Rubin Mucins, Mucus, and Sputum Chest, February 1, 2009; 135(2): 505 - 512. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Lu, B. L. F. Kaplan, T. Ngaotepprutaram, and N. E. Kaminski Suppression of T cell costimulator ICOS by {Delta}9-tetrahydrocannabinol J. Leukoc. Biol., February 1, 2009; 85(2): 322 - 329. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Iribarne, V. Torbidoni, K. Julian, J. P. Prestifilippo, D. Sinha, V. Rettori, A. Berra, and A. M. Suburo Cannabinoid Receptors in Conjunctival Epithelium: Identification and Functional Properties Invest. Ophthalmol. Vis. Sci., October 1, 2008; 49(10): 4535 - 4544. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Buchweitz, P. W. F. Karmaus, K. J. Williams, J. R. Harkema, and N. E. Kaminski Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of {Delta}9-tetrahydrocannabinol J. Leukoc. Biol., March 1, 2008; 83(3): 785 - 796. [Abstract] [Full Text] [PDF] |
||||